Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).
환자-대조
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28
I · Intervention 중재 / 시술
MP and BP assays to classify recurrence risk and molecular subtypes
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
[BACKGROUND] Hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival.
- 표본수 (n) 2732
- p-value p < 0.001
- 연구 설계 case-control
APA
Watanuki R, Sakai H, et al. (2026). Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).. Breast cancer (Tokyo, Japan). https://doi.org/10.1007/s12282-026-01847-2
MLA
Watanuki R, et al.. "Characteristics of a multigene assay (MammaPrint/Blueprint) to predict early recurrence of hormone receptor-positive, HER2-negative breast cancer: a case‒control study (WJOG16722B).." Breast cancer (Tokyo, Japan), 2026.
PMID
41886167 ↗
Abstract 한글 요약
[BACKGROUND] Hormone receptor-positive, HER2-negative (HR + /HER2-) breast cancer generally has a favorable prognosis; however, early postoperative recurrence markedly reduces survival. Accurate prediction of early recurrence is crucial for personalizing treatment. This case-control study compared MammaPrint (MP) and BluePrint (BP) results between early recurrence patients and matched controls.
[METHODS] Patients were selected from our previous study, the WJOG15721B cohort (n = 2732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n = 124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.
[RESULTS] Of 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p < 0.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p < 0.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).
[CONCLUSIONS] Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
[METHODS] Patients were selected from our previous study, the WJOG15721B cohort (n = 2732). Those with recurrence within three years after surgery were randomly extracted, and controls matched for institution, clinical stage, and number of pathological lymph node metastases were included (n = 124). Tumor samples underwent MP and BP assays to classify recurrence risk and molecular subtypes.
[RESULTS] Of 115 submitted tumor samples, 85 were analyzed successfully (43 early recurrence, 42 no recurrence). High-risk MP classification was significantly more frequent in early recurrence patients (79.1% vs. 40.5%, p < 0.001), and Luminal B BP subtype was more common in early recurrence patients (79.1% vs. 38.1%, p < 0.001). High MP risk was associated with high Ki-67 levels and higher nuclear grade. Integrating clinical and genomic risk enhanced prognostic precision: patients with both clinical and genomic high risk had the highest recurrence rate (100%), those with low clinical and genomic risk had the lowest (28.1%), and patients with low clinical but high genomic risk showed an intermediate recurrence rate (57.5%).
[CONCLUSIONS] Compared with patients without recurrence, those with early recurrence showed a significantly higher prevalence of high-risk MP results and Luminal B BP subtype. High-risk MP/Luminal B BP subtype suggested an association with early recurrence in patients with HR + /HER2- early breast cancer.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection.
- A Transformer-Based Deep Learning Model for predicting Early Recurrence in Hepatocellular Carcinoma After Hepatectomy Using Intravoxel Incoherent Motion Images.
- The predictive value of the lymphocyte-C-reactive protein ratio for early recurrence in MVI positive HCC patients who underwent postoperative adjuvant transcatheter arterial chemoembolization.
- Development of a CT radiomics and clinical feature combined model for predicting early recurrence of surgical resected hepatocellular carcinoma.
- A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases.
- Clinical-genomic risk discordance and its impact on treatment selection in premenopausal women with node-positive hormone receptor-positive breast cancer.